NCT03748979View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-925 in Healthy Volunteers and Participants With Narcolepsy

PHASE1CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

November 21, 2018

Primary Completion Date

October 24, 2019

Study Completion Date

October 24, 2019

Conditions
Healthy ParticipantsNarcolepsy
Interventions
DRUG

TAK-925

TAK-925

DRUG

Placebo

TAK-925 Placebo

Trial Locations (3)

Unknown

Sumida Hospital, Sumida-ku

Hakata Clinic, Fukuoka

PS Clinic, Fukuoka

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY